Literature DB >> 7526841

Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators.

L F Lau1, K Pumiglia, Y P Côté, M B Feinstein.   

Abstract

Synthetic thrombin receptor peptides (TRPs), comprising the first 6-14 amino acids of the new N-terminus tethered ligand of the thrombin receptor that is generated by thrombin's proteolytic activity, were reported to activate platelets equally with thrombin itself and are considered to be full agonists [Vu et al. (1991) Cell 64, 1057-1068]. Using aspirin plus ADP-scavengers or the ADP-receptor antagonist adenosine 5'-[alpha-thio]triphosphate to prevent the secondary effects of the potent agonists that are normally released from stimulated platelets (i.e. ADP and thromboxane A2), we assessed the direct actions of thrombin and TRPs (i.e. TRP42-47 and TRP42-55). Compared with thrombin, under these conditions, TRPs: (1) failed to aggregate platelets completely; (2) produced less activation of glycoprotein (GP)IIb-IIIa; (3) did not cause association of GPIIb and pp60c-src with the cytoskeleton; and (4) caused less alpha-granule secretion, phosphorylation of cytoplasmic phospholipase A2, arachidonic acid release and phosphatidyl inositol (PtdOH) production. Furthermore, TRPs induced transient increases in protein phosphorylation mediated by protein kinase C and protein tyrosine phosphorylation, whereas these same responses to thrombin were greater and more sustained. Hirudin added after thrombin accelerated protein dephosphorylation, thereby mimicking the rate of spontaneous dephosphorylation seen after stimulation by TRPs. Platelets totally desensitized to very high concentrations of TRPs, by prior exposure to maximally effective concentrations of the peptides, remained responsive to alpha- and gamma-thrombins. Thrombin-stimulated PtdOH production in permeabilized platelets desensitized to TRPs was abolished by guanosine 5'-[beta-thio]diphosphate (GDP[beta S]), as in normal platelets. These results are discussed in terms of the allosteric Ternary Complex Model for G-protein linked receptors [Samama et al. (1993) J. Biol. Chem. 268, 4625-4636]. We conclude that: (1) TRPs are partial agonists for the thrombin receptor and produce incomplete receptor desensitization in keeping with their lower intrinsic activity; (2) thrombin's effects in platelets, even in TRP-desensitized platelets, are entirely mediated through the recently cloned G-protein linked receptor, and (3) thrombin's ability to produce sustained signals, compared with TRPs, may require the continued progressive proteolytic activation of naive thrombin receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526841      PMCID: PMC1137340          DOI: 10.1042/bj3030391

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  59 in total

1.  Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process.

Authors:  Y F Su; T K Harden; J P Perkins
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

2.  Dissociation of thrombin from platelets by hirudin. Evidence for receptor processing.

Authors:  S W Tam; J W Fenton; T C Detwiler
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

3.  Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid.

Authors:  L L Lin; A Y Lin; J L Knopf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

4.  Thrombin receptor 14-amino acid peptide mediates endothelial hyperadhesivity and neutrophil adhesion by P-selectin-dependent mechanism.

Authors:  Y Sugama; A B Malik
Journal:  Circ Res       Date:  1992-10       Impact factor: 17.367

5.  Activation of signal transduction in platelets by the tyrosine phosphatase inhibitor pervanadate (vanadyl hydroperoxide).

Authors:  K M Pumiglia; L F Lau; C K Huang; S Burroughs; M B Feinstein
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

6.  Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function.

Authors:  R M Scarborough; M A Naughton; W Teng; D T Hung; J Rose; T K Vu; V I Wheaton; C W Turck; S R Coughlin
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

7.  Essential groups in synthetic agonist peptides for activation of the platelet thrombin receptor.

Authors:  B H Chao; S Kalkunte; J M Maraganore; S R Stone
Journal:  Biochemistry       Date:  1992-07-14       Impact factor: 3.162

8.  Molecular cloning of the rat vascular smooth muscle thrombin receptor. Evidence for in vitro regulation by basic fibroblast growth factor.

Authors:  C Zhong; D J Hayzer; M A Corson; M S Runge
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

9.  Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus.

Authors:  L F Brass; R R Vassallo; E Belmonte; M Ahuja; K Cichowski; J A Hoxie
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

10.  Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion.

Authors:  Y Sugama; C Tiruppathi; K offakidevi; T T Andersen; J W Fenton; A B Malik
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  13 in total

1.  A molecular mechanism for signaling between seven-transmembrane receptors: evidence for a redistribution of G proteins.

Authors:  Y Djellas; K Antonakis; G C Le Breton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

2.  YD-3, a novel inhibitor of protease-induced platelet activation.

Authors:  C C Wu; S W Huang; T L Hwang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 3.  Cellular consequences of thrombin-receptor activation.

Authors:  R J Grand; A S Turnell; P W Grabham
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

Review 4.  The cellular basis of platelet secretion: Emerging structure/function relationships.

Authors:  Shilpi Yadav; Brian Storrie
Journal:  Platelets       Date:  2016-12-23       Impact factor: 3.862

5.  Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases.

Authors:  Ada W Y Chung; Anna Radomski; David Alonso-Escolano; Paul Jurasz; Michael W Stewart; Tadeusz Malinski; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2004-11-08       Impact factor: 8.739

6.  Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist.

Authors:  L Ma; M D Hollenberg; J L Wallace
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

7.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

8.  A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation.

Authors:  F A Ofosu; J Freedman; L Dewar; Y Song; J W Fenton
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

9.  TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural features.

Authors:  Berta Fusté; Maribel Díaz-Ricart; Morten Krogh Jensen; Antonio Ordinas; Ginés Escolar; James G White
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

10.  The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function.

Authors:  Francisca C Gushiken; Han Hyojeong; Subhashree Pradhan; Kimberly W Langlois; Nawaf Alrehani; Miguel A Cruz; Rolando E Rumbaut; K Vinod Vijayan
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.